Repligen Corp. (RGEN)

35.37
NASDAQ : Health Technology
Prev Close 34.98
Day Low/High 34.32 / 35.59
52 Wk Low/High 29.56 / 46.81
Avg Volume 257.30K
Exchange NASDAQ
Shares Outstanding 43.56M
Market Cap 1.41B
EPS 0.70
P/E Ratio 48.58
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BIO, BURL, DHT, GSAT, LGIH, NAP, ORA, PENN, VJET, XNET Downgrades: ARCC, BHE, FLWS, GPS, JOBS, MNRO, RGEN, TRGP, ZAYO Initiations: ACIU, AZRE, DTV Read on to get TheStreet Quant Ratings' detailed report:

Repligen To Report Third Quarter 2017 Financial Results

Repligen To Report Third Quarter 2017 Financial Results

Webcast and Conference Call to Be Held Thursday, November 9, 2017 at 8:30 a.m. EST

RGEN Crosses Above Average Analyst Target

In recent trading, shares of Repligen Corp. have crossed above the average analyst 12-month target price of $42.80, changing hands for $43.67/share.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BUFF, PRIM, QTRH, RGEN, WBT Downgrades: AGM, AHC, BHB, CLSD, EVK, GTIM, MLNX, OBCI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Repligen To Report Second Quarter 2017 Financial Results

Repligen To Report Second Quarter 2017 Financial Results

Webcast and Conference Call to Be Held Thursday, August 3, 2017 at 8:30 a.m. EDT

Short Interest In Repligen Declines 10.5%

The most recent short interest data has been released for the 06/15/2017 settlement date, which shows a 389,232 share decrease in total short interest for Repligen Corp. , to 3,322,230, a decrease of 10.49% since 05/31/2017.

Repligen Reaches Analyst Target Price

In recent trading, shares of Repligen Corp. have crossed above the average analyst 12-month target price of $38.80, changing hands for $38.99/share.

Repligen To Report First Quarter 2017 Financial Results

Webcast and Conference Call to Be Held Thursday, May 4, 2017 at 8:30 a.m. EDT

Repligen Reaches Analyst Target Price

In recent trading, shares of Repligen Corp. have crossed above the average analyst 12-month target price of $35.33, changing hands for $35.35/share.

Repligen To Report Fourth Quarter And Full Year 2016 Financial Results, Provides Financial Guidance For 2017

Webcast and Conference Call to Be Held Wednesday, February 22, 2017 at 8:30 a.m. EST

Notable Two Hundred Day Moving Average Cross - RGEN

Notable Two Hundred Day Moving Average Cross - RGEN

In trading on Tuesday, shares of Repligen Corp. crossed below their 200 day moving average of $29.07, changing hands as low as $28.53 per share.

Drug Stocks Find Trump Animus a Bitter Pill

Drug Stocks Find Trump Animus a Bitter Pill

The president-elect's words rattled the sector, though Amgen appears to be shrugging off his remarks.

TheStreet Quant Rating: C (Hold)